Ondine Biomedical (LON:OBI) Sets New 1-Year High - Still a Buy?

Key Points

• Ondine Biomedical shares reached a new 52-week high at C$18.50, with the last trading price at C$17.60 and a significant trading volume of over 1.1 million shares.
• The company has a debt-to-equity ratio of 25.95 and a market capitalization of C$125.83 million, suggesting a challenging financial structure amidst its growth phase.
• Ondine Biomedical specializes in photodisinfection-based therapies aimed at preventing and treating infections, including those from antimicrobial-resistant pathogens.

Ondine Biomedical Inc. (LON:OBI - ) shares hit a new 52-week high on Tuesday . The company traded as high as C$18.50 and last traded at C$17.60, with a volume of 1115143 shares changing hands. The stock had previously closed at C$18.00.

Ondine Biomedical Stock Performance

The stock's 50-day moving average price is C$13.47 and its 200 day moving average price is C$11.14. The company has a debt-to-equity ratio of 25.95, a current ratio of 1.36 and a quick ratio of 8.26. The firm has a market cap of C$125.83 million, a P/E ratio of -5.27 and a beta of 0.10.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.